Trial Profile
A Phase 1 Study of ACTR087, an Autologous T Cell Product, in Combination With SEA-BCMA, a Monoclonal Antibody, in Subjects With Relapsed or Refractory Multiple Myeloma
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 10 Nov 2020
Price :
$35
*
At a glance
- Drugs ACTR-087/SEA-BCMA-combination-therapy (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions; First in man
- Sponsors Seagen
- 10 Feb 2020 Status changed from active, no longer recruiting to discontinued.
- 08 Jan 2020 Status changed from recruiting to active, no longer recruiting.
- 04 Nov 2019 According to an Unum Therapeutics media release, two additional cohorts of patients have been treated in this study ( escalating doses : SEA-BCMA to 2.0 mg/kg and ACTR087+ T cells to 50M ). The company have suspended the further dose-escalation of the study.